Selank vs Semax: Anxiety Research vs Cognitive Enhancement, Compared

Both Selank and Semax emerged from decades of Soviet-era and post-Soviet neuropharmacology research at the Russian Academy of Sciences. Both have clinical registration in Russia for specific indications. Both are peptide-based, both are administered intranasally in published protocols, and both affect the central nervous system.

The design intentions were different. Selank was developed with anxiolytic research as the primary goal - its molecular design drew from the sequence of the endogenous immunomodulatory peptide tuftsin, with modifications targeting anxiety-relevant mechanisms. Semax was developed from a fragment of ACTH (adrenocorticotropic hormone, the pituitary hormone that regulates the adrenal stress response and has documented cognitive and neuroprotective effects).

Both compounds converge on BDNF as a shared downstream target, which is where their otherwise divergent research profiles intersect.

For detailed compound research: Selank Research Guide · Semax Research Guide.

Selank's primary documented mechanism involves modulation of the GABAergic system. Unlike classic benzodiazepines, Selank does not appear to bind directly to the GABA-A receptor (the ionotropic inhibitory receptor that benzodiazepines potentiate) but instead modulates the availability and metabolism of endogenous GABA receptor ligands, including enkephalins (endogenous opioid peptides that modulate pain, stress, and anxiety signaling).

Selank has also been documented to increase BDNF (brain derived neurotrophic factor, the primary growth factor for synapse formation, neuroplasticity, and neuron survival in the central nervous system) expression in published preclinical research. This BDNF upregulation may contribute to the anxiolytic and stress-buffering effects observed in clinical research.

The Russian clinical research literature documents Selank's use in anxiety disorder research, where it produced anxiolytic effects with a different side effect profile than benzodiazepine class compounds - notably without the sedation and cognitive impairment commonly associated with GABAergic anxiolytics.

Semax (ACTH(4-7)PGP, a synthetic heptapeptide derived from the ACTH fragment 4-7 with a proline-glycine-proline extension that increases stability and CNS penetration) acts through multiple documented CNS mechanisms. Its most consistently reported action in the published literature is upregulation of BDNF and related neurotrophins, particularly in hippocampal and cortical tissue.

Semax also modulates dopaminergic (relating to the dopamine neurotransmitter system, involved in motivation, working memory, and executive function) and serotonergic (relating to the serotonin system, involved in mood, sleep, and cognition) signaling. Published electrophysiological research documents changes in neural circuit activity following Semax administration.

The cognitive and neuroprotective effects documented in Russian clinical research - including post-stroke recovery protocols and cognitive enhancement in healthy subjects - reflect a compound designed to activate, protect, and enhance neural function rather than to calm it.

The most significant overlap between Selank and Semax is their shared capacity to upregulate BDNF. This is not coincidental - it reflects the fact that BDNF is a central mechanism in both anxiety resolution and cognitive enhancement.

Anxiety chronically suppresses BDNF expression, particularly in the hippocampus, via the stress hormone cortisol. Selank-mediated anxiety reduction may allow BDNF expression to recover toward baseline. Semax directly drives BDNF upregulation through a different pathway. Both compounds arrive at elevated BDNF through different routes.

This shared BDNF convergence is why researchers sometimes study both compounds together - one addressing the anxiety-driven suppression of neuroplasticity, the other directly driving neuroplasticity enhancement.

The simplest way to characterize the divergence: Selank calms, Semax activates. Selank is registered in Russia for anxiety disorders. Semax is registered for stroke recovery and cognitive impairment. These different clinical targets reflect genuinely different pharmacological profiles.

In published research, Selank tends to produce sedation-adjacent effects at higher doses - consistent with its GABAergic mechanism. Semax tends to produce stimulatory and activating effects - consistent with its dopaminergic and BDNF-driven mechanisms. Researchers report meaningfully different subjective and objective response profiles between the two compounds.

Route overlap (both primarily intranasal in published protocols) and behavioral overlap (both affect CNS function) can obscure this fundamental divergence in research goal and pharmacological profile.

Both compounds are primarily studied via intranasal administration in published Russian clinical research. This route exploits the olfactory pathway for direct CNS delivery, bypassing the blood brain barrier challenge that would otherwise limit CNS bioavailability for peptides of this size.

Published Selank protocols in the Russian clinical literature use intranasal administration with dosing typically in the 200 to 900 mcg range, with cycle lengths of 2 to 4 weeks. Semax published protocols similarly use intranasal administration with doses typically ranging from 200 mcg to 600 mcg per administration, with research cycles varying by indication.

Both compounds have published data on tolerance development with prolonged continuous use, which contributes to the cycling protocols common in the research literature.

The mechanistic rationale for combining Selank and Semax draws on the relationship between anxiety and cognition. Chronic anxiety suppresses hippocampal neuroplasticity and working memory through cortisol-mediated BDNF suppression. Selank addresses the anxiety state that is suppressing neuroplasticity. Semax then has a clearer substrate on which to drive BDNF-mediated enhancement.

Published research has not systematically evaluated the combination in controlled trials, but mechanistic reasoning from the individual compound literature suggests complementary rather than competing effects. The two compounds address different constraints on optimal CNS function.

Researchers interested in both compounds should review the individual compound literature and published combination protocol discussions in the research community before designing protocols.

Researchers studying anxiolytic and cognitive enhancement mechanisms can review Selank and Semax product specifications. Both compounds are third party tested with batch-specific COA documentation. For a broader overview of neuropeptide research, see cognitive peptides compared and the peptides for anxiety guide.

For anxiety-focused research: Selank is the primary compound. It reduces anxiety without sedation and has been studied specifically as an anxiolytic in Russian clinical settings.

For cognitive enhancement research: Semax is the primary compound. BDNF upregulation is its best-characterized mechanism and the most relevant to learning and memory research.

Selank + Semax stack: The combination is common in Russian research. Selank handles the anxiety and stress-reduction component while Semax handles cognitive enhancement. Effects are additive rather than redundant.

*Both are approved drugs in Russia. Neither is FDA-approved. For research purposes only.*

For the full scope of cognitive enhancement and neuroprotection peptide research, see the Cognitive Enhancement Research Guide.